OR WAIT null SECS
August 15, 2025
Article
The accelerated approval is based on findings from Part 1 of the ESSENCE trial and indicates the agent for noncirrhotic MASH with moderate to advanced fibrosis.
August 08, 2025
Cholesterol in liver fat droplets has been found as a key driver of liver inflammation and fibrosis.
August 07, 2025
Co-locating ID screening in an inpatient SUD program resulted in timely identification of and linkage to care for viral hepatitis and latent tuberculosis.
August 04, 2025
Check out expert perspectives and new research on hepatitis C, cirrhosis, and more in this July 2025 recap.
July 29, 2025
Study findings suggest significant sex disparities in liver complication risk among adult patients with cirrhosis, especially in the context of nonviral cirrhosis.
The unsaturated fats from vegetable oils reduce inflammation and influence organ metabolism, resulting in lowered ALT, AST, and TBIL indexes.
July 28, 2025
A multidisciplinary care program achieved a 95% cure rate with Sofosbuvir/Velpatasvir therapy.
Deming explains drivers of new infections, systemic barriers impeding progress, and the changes she believes are needed to aid elimination efforts.
July 24, 2025
Video
Holden describes the importance of including SLD in global health policy frameworks and how a side event at the 78th WHA sought to address current gaps.
July 23, 2025
Sanyal describes the growing burden of SLD and its connection to other major chronic diseases, underscoring the need for better recognition and prevention efforts.
